Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 9/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.41 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.41 |
| ▸ | LIPC | P11150 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | LIPE | Q05469 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3884175 | 0.78 | MAOB (0.44) | BCHEMAOBCYP4F2CYP4A11MME | |
| SCHEMBL3886612 | 0.73 | BCHE (0.49) | BCHEMAOBCYP4F2CYP4A11 | |
| SCHEMBL13434095 | 0.71 | MAOB (0.73) | BCHEMAOBCYP4F2CYP4A11LTB4R | |
| SCHEMBL25922339 | 0.71 | SIGMAR1 (0.47) | FFAR1BCHEMAOB | |
| SCHEMBL14021492 | 0.71 | CYP4F2 (0.47) | FFAR1BCHEMAOBCYP4F2CYP4A11 | |
| SCHEMBL704303 | 0.70 | MAOB (0.51) | BCHEMAOBCYP4F2CYP4A11 | |
| SCHEMBL14021848 | 0.70 | CYP4F2 (0.52) | FFAR1BCHEMAOBCYP4F2CYP4A11 | |
| SCHEMBL321092 | 0.70 | MAOB (0.62) | BCHEMAOBCYP4F2CYP4A11MME | |
| SCHEMBL24645961 | 0.69 | MAOB (0.57) | BCHEMAOBCYP4F2CYP4A11MME | |
| SCHEMBL24646119 | 0.69 | MAOB (0.57) | BCHEMAOBCYP4F2CYP4A11MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | claimed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | claimed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| EP-1511483-A4 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060020036-A1 | Methods and compositions to promote bone homestasis | GALAPAGOS N.V. (BE) | 2006-01-26 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050171084-A1 | Methods of treatment with lxr modulators | SMITHKLINE BEECHAM CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| EP-1511483-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082198-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | FFAR1 28/4885BCHE 2160/4885MAOB 3322/4885 |
| US-20050171084-A1 | Methods of treatment with lxr modulators | NR1H2, NR1H3, NR1H4 | FFAR1 149/4885BCHE 2442/4885MAOB 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.